参考文献/References:
[1] Howell RW.Radiation spectra for Auger-electron emitting radionuclides:report No.2 of AAPM nuclear medicine task group No.6[J].Med Phys, 1992, 19:1372-1382.
[2] Stepanek J, Larsson B, Weinreich R.Auger electron spectra of radionuclides for therapy and diagnostics[J].Acta Oncol, 1996, 35:863-868.
[3] Sastry KSR.Biological effects of Auger emitter iodine-125[J].Med Phys, 1992, 19:1361-1370.
[4] Narra V R, Howell RW, Harapanhalli RS, et al.Radiotoxicity of some iodine-123, iodine-125 and iodine-131-labled compounds in mouse tests:implications for radiopharmaceutical design[J].J Nucl Med, 1992, 33:2196-2201.
[5] Faraggi M, Gardin I, Mmoretti JL, et al.Comparison of cellular and conventional dosimetry in assessing self-dose and cross-dose delivered to the cell nucleus by electron emissions of Tc-99 m, I-123, In-111, Ga-67 and Tl-201[J].Eur J Nucl Med, 1998, 25:205-214.
[6] Hartman T, Lundqvist H, Westlin JE, et al.Radiation doses to the cell nucleus in single cells and cells in micrometastases in targed therapy with 131-I labeled ligands or antibodies[J].Int J Radiat Oncol Biol Phys, 2000, 46(4):1025-1036.
[7] Spinelli F, Sare R, Milella M, et al.Technotium-99m hexamethylpropylene axnine oxine leucocyte scintigraphy in the differential diagnosis of cerebral abscesses[J].Eur J Nucl Med, 2000, 27(1):46-49.
[8] Garcferndez R, Lwasaki I, Acosta F, et al.Scintigraphy with erythrocytes labelled in vitro with 99Tcm compared with 111In-octreptide in the detection of carotid glomus[J].Rev Invest Clin, 2000, 52(1):25-30.
[9] Narra V R, Sastry KRS, Goddu SM, et al.Relative biological effectiveness of Tc-99m radio-pharmaceuticals[J].Med Phys, 1994, 21:1921-1926.
[10] de Labriolle-Vayler C, Colas-Linhart N, Sala-Trepat M, et al.Biological consequence of the heterogeneous irradiation of lymphocytes during technetium-99m hexamethylpropylene amine oxime white blood cells labeling[J].Eur J Nucl Med, 1998, 25:1423-1428.
[11] Marjorie S, Nicole C, Colas-Linhart, et al.Heteroge-neous distribution of technetium-99m-labeled micro-spheres in rat lungs:microautoradiographic evidence and dosimetric consequences[J].J Nucl Med, 1997, 38:650-654.
[12] Puncher MRB, Blower PJ.Fronzen section microau-toradiography in the study of radionuclide targeting:application to indium-111-oxime-labled leucocytes[J].J Nucl Med, 1995, 36:499-505.
[13] Gardin I, Faraggi M, Huc E, et al.Modelling of the relationship between cell dimensions and mean dose delivered to the cell nucleus:application to five radionuclides used in nuclear medicine[J].Phys Med Biol, 1995, 40:1001-1014.
[14] Gardin I, Colas-Linhart N, Petiet A, et al.dosimetryat the cellular level of kupffer cells after technetium-99m-sulphur colloid injection[J].J Nucl Med, 1992, 33:380-384.
[15] Ernst M, Freed M E, Zametkin AJ.Health hazards of radiation exposure in the context of brain imaging research:special consideration for children[J].J Nucl Med, 1998, 39:689-698.
相似文献/References:
[1]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[2]甘红梅,乔晋萍,孔爱英,等.正电子放射性显像剂代谢及其研究方法进展[J].国际放射医学核医学杂志,2010,34(2):65.[doi:10.3760/cma.j.issn.1673-4114.2010.02.001]
GAN Hong-mei,QIAO Jin-ping,KONG Ai-ying,et al.The progress on researching method and metabolism of positron radiopharmaceutical[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):65.[doi:10.3760/cma.j.issn.1673-4114.2010.02.001]
[3]顾涛颖,石洪成.放射性药物治疗肿瘤骨转移性骨痛的作用[J].国际放射医学核医学杂志,2010,34(2):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]
GU Tao-ying,SHI Hong-cheng.The use of radiopharmaceuticals for metastatic bone pain in cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):88.[doi:10.3760/cma.j.issn.1673-4114.2010.02.006]
[4]周雪,乔晋萍,孔爱英,等.受体结合实验及其在放射性显像剂研究中的应用进展[J].国际放射医学核医学杂志,2010,34(6):321.[doi:10.3760/cma.j.issn.1673-4114,2010.06.001]
ZHOU Xue,QIAO Jin-ping,KONG Ai-ying,et al.Progress on the application of ligand receptor binding assays in radiopharmaceuticals[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(4):321.[doi:10.3760/cma.j.issn.1673-4114,2010.06.001]
[5]彭添兴,吴华.18F-氟脱氧葡萄糖以外新型PET肿瘤显像剂[J].国际放射医学核医学杂志,2007,31(1):9.
PENG Tian-xing,WU Hua.New type PET imaging agent excluding 18F-fluorodeoxyglucose in oncology[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):9.
[6]范我.用于肿瘤治疗的放射性药物[J].国际放射医学核医学杂志,2004,28(1):21.
FAN Wo.Radiopharmaceuticals for tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(4):21.
[7]陈璟,吴华.核素炎症显像的研究进展[J].国际放射医学核医学杂志,2003,27(3):107.
CHEN Jing,WU Hua.The development of radionuclide imaging of infection and inflammation[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(4):107.
[8]杨建权,李晔,张现忠.基于小分子肽的放射性药物[J].国际放射医学核医学杂志,2003,27(4):157.
YANG Jian-quan,LI Ye,ZHANG Xian-zhnng.Peptide as carrier for diagnosis and treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(4):157.
[9]袁志斌.获得FDA批准的放射性药物[J].国际放射医学核医学杂志,2000,24(4):161.
YUAN Zhi-bin.FDA approved radiopharmaceuticals[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(4):161.
[10]弓全胜,夏振民.放射性药物的给药后归宿[J].国际放射医学核医学杂志,1998,22(4):167.